Better management for dolutegravir-resistant HIV
Part of Infections clinical trials.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are at least 1 year old.
- You have a confirmed HIV-1 infection.
- You have been taking a dolutegravir (DTG)-containing regimen for at least 6 months.
- Your most recent HIV viral load test (within the last 3 months) was 1,000 copies/mL or higher.
- You have not switched your HIV medicines because of treatment failure while on a protease inhibitor (PI) or integrase inhibitor (INSTI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study collects information from people with HIV who are either starting HIV treatment for the first time or switching from a three-drug regimen to a two-drug regimen with dolutegravir and lamivudine. The goal is to build a database to learn how well this dual therapy works in real-world practice.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.